MedTrace Logo

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

NCT00743431 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 224

Last updated 2015-04-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-plantar erythrodysesthesia.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

Caelyx (Pegylated Lyposomal Doxorubicin)

Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.

Sponsors & Collaborators

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-12-31
Completion
2008-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00743431 on ClinicalTrials.gov